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Summary
BRIT1, initially identified as an hTERT repressor, has additional functions at DNA damage checkpoints. Here, we demon-
strate that BRIT1 formed nuclear foci minutes after irradiation. The foci of BRIT1 colocalized with 53BP1, MDC1, NBS1,
ATM, RPA, and ATR. BRIT1 was required for activation of these elements, indicating that BRIT1 is a proximal factor in the
DNA damage response pathway. Depletion of BRIT1 increased the accumulation of chromosomal aberrations. In addition,
decreased levels of BRIT1were detected in several types of human cancer, with BRIT1 expression being inversely correlated
with genomic instability and metastasis. These results identify BRIT1 as a crucial DNA damage regulator in the ATM/ATR
pathways and suggest that it functions as a tumor suppressor gene.Introduction
Maintenance of genomic integrity in the face of mutagenic ef-
fects of DNA damage relies on flawless execution of genome
surveillance pathways, checkpoints that coordinate cell cycle
progression with DNA repair (Nyberg et al., 2002; Zhou and
Elledge, 2000). In response to DNA damage, mammalian cells
initiate a cascade of phosphorylation events mediated by two
phosphatidylinositol-3-related kinases, ATM (ataxia telangiec-
tasia mutated) and ATR (ATM-Rad3-related), which phosphory-
late and activate a variety ofmolecules to execute theDNAdam-
age response (Osborn et al., 2002; Shiloh, 2001, 2003). ATM is
activated primarily by double-strand breaks (DSBs) induced
by ionizing radiation, whereas ATR also responds to ultraviolet
(UV) radiation or stalled replication forks (Osborn et al., 2002).
The current model of the DNA damage response describes a lin-
ear progression beginning with sensors that convey the initial
damage signal to mediators and transducers, which in turn
transmit the signal to numerous effectors. During the past few
years, many studies have been conducted on how damage sig-
nals coordinately execute cellular responses to DNA damage;
however, much less is known about themechanisms that initiateCANCER CELL 10, 145–157, AUGUST 2006 ª2006 ELSEVIER INC. DOI 1the early events prompted by DNA damage that precede the
spread of the damage signal throughout the cell.
Sensors and early mediators are molecules that, after DNA
damage, are promptly recruited to the damaged DNA structure
and phosphorylated by ATM, ATR, or both; they then in turn
transmit the signals to downstream transducers and effectors
(Sancar et al., 2004). The Mre11/Rad50/NBS1 complex,
MDC1, 53BP1, RPA, and Rad17 are all components of the early
DNA damage response complex; defects in these molecules
disrupt the dedicated DNA damage response and lead to geno-
mic instability and cancer development (DiTullio et al., 2002;
Gorgoulis et al., 2005; Kang et al., 2005; Wang et al., 2002,
2005a; Ward et al., 2003).
We previously identified BRIT1 (BRCT-repeat inhibitor of
hTERT expression) in a genetic screen for transcriptional repres-
sors of hTERT, the catalytic subunit of human telomerase (Lin
and Elledge, 2003). The sequence of BRIT1 was derived from
a hypothetical protein that was later matched to a putative dis-
ease gene called microcephalin (MCPH1), one of at least six loci
implicated in the autosomal recessive disease primary micro-
cephaly (Jackson et al., 2002). Recently, we and others showed
that BRIT1 is required for DNA damage-induced intra-S andS I G N I F I C A N C E
The human genome is constantly challenged by endogenous and environmental factors that can alter its structure and corrupt its en-
codedmessage. A signaling network of checkpoint pathways has evolved to respond to these challenges tomaintain genomic integ-
rity. Our studies indicate that BRIT1 functions as aproximal factor in theDNAdamagecheckpoints that controlmultiple damage sensors
and early mediators. Disruption of BRIT1 function abolishes DNA damage responses and leads to genomic instability. Furthermore, ab-
errations of BRIT1 have been identified in several cancer lineages that link its deficiency to cancer initiation andprogression. Thus, BRIT1
may function as a tumor suppressor, and as such, further understanding of its functionmaywell contribute to novel, effective therapeu-
tic approaches for cancer.0.1016/j.ccr.2006.07.002 145
A R T I C L EFigure 1. BRIT1 forms IRIF immediately after IR and is required for NBS1, 53BP1, MDC1, and p-ATM IRIF formation
A: U2OS cells were analyzed for IRIF formation at the indicated times after irradiation (10 Gy).
B: U2OS cells were transfected with control (luciferase) or BRIT1 siRNA#1 twice as described; 48 hr after the second transfection, cells were treated or not
treated with 10 Gy of ionizing radiation, and 1 hr later they were fixed and stained with antibodies to BRIT1 and 53BP1. Cells were then washed and stained
with rhodamine- or FITC-conjugated antibodies; nuclei were visualized by DAPI staining. The 53BP1 foci were abolished in cells in which BRIT1 was completely
knocked down; the cells with incomplete knockdown of BRIT1 did show 53BP1 foci (bottom panel).
C: U2OS cells were transfected and treated as described in B except that the antibodies used were to BRIT1 and MDC1 (top) or BRIT1 and p-ATM (bottom).
D: U2OS cells were transfected and treated as described for B except that the antibodies used were to BRIT1 and NBS1. Scale bars, 20 mm.G2/M checkpoints and that this requirement may result in part
from its regulation of the expression of BRCA1 and Chk1 (Lin
et al., 2005; Xu et al., 2004). We also demonstrated that BRIT1
is a chromatin binding protein that forms irradiation-induced nu-
clear foci (IRIF), which colocalize with g-H2AX (Lin et al., 2005).
These observations suggested that BRIT1 may have a direct
role in transmitting DNA damage signals.
In this study, we report that BRIT1 colocalizes with several
DNA damage sensors and early mediators upon DNA damage
and is required for IRIF formation, chromatin binding, and phos-
phorylation of these molecules in the ATM/ATR pathways. Fur-
thermore, BRIT1 is required for chromosomal integrity in human
cells, as demonstrated by reductions in gene copy numbers and
expression in several cell lineages that correlate with tumor be-
havior. Thus, we propose that BRIT1 functions as an upstream
component of the DNA damage pathway that recruits sensors146and mediators to damaged DNA loci contributing to genomic
stability, suggesting that BRIT1 may be an as yet unidentified
tumor suppressor gene in multiple cancer lineages.
Results
BRIT1 is required for the formation of irradiation-induced
nuclear foci by NBS1, 53BP1, MDC1, and phosphorylated
ATM
When DNA is damaged in cells, many DNA damage-signaling
proteins are recruited to the damaged loci and form discrete nu-
clear foci (IRIF) (Paull et al., 2000; Rouse and Jackson, 2002). The
order and timing of these events are thought to be critical for
checkpoint response and DNA repair (Stewart et al., 2003).
Also, a hierarchyof proteins seems tobe involved in theassembly
of IRIF, and the resultant hierarchy of foci formation providesCANCER CELL AUGUST 2006
A R T I C L EFigure 2. BRIT1 is required for UV-induced formation of ATR, RPA, and p-Rad17 foci
U2OS cells were transfected with control (luciferase) or BRIT1 siRNA twice; at 48 hr after the second transfection, cells were treated or not treated with 50 J/m2
of UV radiation. One hour after irradiation, cells were fixed and costained with antibodies to BRIT1 and ATR (A), RPA34 (B), p-RPA34 (C, left panel), and p-Rad17
(C, right panel). Cells were then washed and stained with rhodamine- or FITC-conjugated antibodies. Nuclei were visualized by DAPI staining. Scale bars,
20 mm.a means of ordering the molecular events ensuing from DNA
damage detection and signal transduction (Petrini and Stracker,
2003). To dissect the role of BRIT1 in checkpoint signaling and its
positionwithin thesignalingpathway,wefirst studiedhowquickly
BRIT1 formed IRIF following DNA damage and the hierarchy be-
tween recruitment of BRIT1 and other key checkpoint regulators.
As shown in Figure 1A, BRIT1 formed IRIF very promptly; the
BRIT1 foci could be detected as early as 2 min after ionizing ir-
radiation. This result placed BRIT1 very upstream of the DNA
damage signaling. Previously, we demonstrated that BRIT1 co-
localized with g-H2AX (Lin et al., 2005), one of the earliest mol-
ecules to respond to DNA damage (Paull et al., 2000). However,
depletion of BRIT1 by small interfering RNA (siRNA) did not abol-
ish the formation of g-H2AX foci, suggesting that g-H2AX foci
formation was not regulated by BRIT1 (data not shown). Thus,
BRIT1 may function in parallel with or downstream of g-H2AX.
Based on current model, after ionizing irradiation, g-H2AX
marks the chromatin region at or near the DNA damage site
and serves as a platform for the recruitment of DNA checkpoint
signaling and repair factors including 53BP1, MDC1, MRN
(MRE11-RAD50-NBS1), andBRCA1 (Carneyet al., 1998;Celeste
et al., 2002; Goldberg et al., 2003; Lou et al., 2003; Paull et al.,CANCER CELL AUGUST 20062000; Rappold et al., 2001; Scully et al., 1997; Stewart et al.,
2003; van den Bosch et al., 2003; Wang et al., 2002; Xu and
Stern, 2003; Zhong et al., 1999). The appearance of 53BP1,
MDC1, and NBS1 foci seems to be coincident with formation
of the g-H2AX foci (Thompson and Limoli, 2003). To determine
whether BRIT1 functions in the early damage response, we
tested whether BRIT1 colocalized with these proteins after ioniz-
ing irradiation and whether BRIT1 expression was required for
the formation of IRIF containing these early response elements.
We first analyzed IRIF formation using immunofluorescence
staining with specific antibodies to BRIT1, 53BP1, MDC1, phos-
pho- (p-) ATM (p-S1981), and NBS1. After ionizing irradiation,
numbers of BRIT1 foci sharply increased and colocalized with
53BP1 foci (Figure 1B), MDC1 and p-ATM foci (Figure 1C),
and NBS1 foci (Figure 1D). Moreover, depletion of BRIT1 by
BRIT1-specific siRNA, but not a control luciferase siRNA, abol-
ished the formation of the IRIF containing each of these mole-
cules. These results were confirmed using two additional
BRIT1 siRNAs (not presented), the specificity of which has
been demonstrated previously (Lin et al., 2005). Moreover, the
foci formation could be restored when siRNA-resistant BRIT1
was ectopically expressed (Figure S1 in the Supplemental147
A R T I C L EData available with this article online shows the rescue of MDC1
foci as one of the examples). These results suggest that BRIT1 is
likely to function upstream of 53BP1, MDC1, and theMRN com-
plex and is required for the recruitment of active p-ATM to the
damaged loci, through direct binding or indirectly through bridg-
ing via 53BP1, MDC1, or NBS1.
BRIT1 is required for the formation of UV-induced ATR,
RPA, and p-Rad17 foci
To determine if BRIT1 plays a parallel role in regulation of the
ATR pathway, we used coimmunostaining of BRIT1 protein
with three known sensors or early mediators in the ATR path-
way—ATR, RPA, and Rad17 (Unsal-Kacmaz et al., 2002; Zou
and Elledge, 2003; Zou et al., 2003; Sancar et al., 2004).
We found that BRIT1 formed discrete foci after UV irradiation
(Figure 2), which colocalized with ATR and RPA (Figures 2A and
2B). siRNA knockdown showed that BRIT1 was required for the
formation of ATR and RPA foci (Figures 2A and 2B), indicating
that BRIT1 is required for proper ATRandRPA translocation after
UV irradiation. The rescue of RPA foci was also demonstrated
when siRNA-resistant BRIT1 was ectopically expressed (Fig-
ureS2). TheRPA foci, however, could notbe restoredwheneither
BRCA1 and/or Chk1 was ectopically expressed, indicating that
BRIT1 regulated RPA foci through a mechanism independent of
its regulation on BRCA1/Chk1 expression (Figure S2).
Both RPA and Rad17, another checkpoint protein that serves
as a sensor after UV exposure, bind to the damaged DNA and
are phosphorylated by ATR (Zou et al., 2002; Zou and Elledge,
2003). BRIT1 was also required for the phosphorylation of
both RPA and Rad17 (Figure 2C), compatible with a lack of re-
cruitment of RPA and Rad17 to the damaged DNA loci or of
the failure of recruitment of ATR to the complex.
Together, these findings implicate BRIT1 in signaling up-
stream of foci formation in both the ATM and ATR pathways.
BRIT1 is required for the association of MDC1, 53BP1,
p-NBS1, RPA, and p-Rad17 with chromatin
DNA damage results in enhanced binding of checkpoint regula-
tors including MDC1, 53BP1, NBS1, RPA, and Rad17 to chro-
matin (Liu et al., 2001; Peng and Chen, 2005; Zou et al., 2002,
2003; Zou and Elledge, 2003). The association of these factors
with chromatin is thought to take place in parallel with their
recruitment into IRIF on damaged DNA.
Because BRIT1 is a chromatin binding protein (Lin et al., 2005)
and is required for the recruitment of sensors and early media-
tors to damaged DNA loci, we expected that BRIT1 depletion
would also abolish the damage-induced binding of these mole-
cules to chromatin, as assessed by chromatin fractionation
analysis (Lin et al., 2005). Indeed, depletion of BRIT1 by two spe-
cific BRIT1 siRNAs in U2OS cells markedly reduced both basal
and ionizing irradiation-induced association of MDC1, 53BP1,
and p-NBS1 with chromatin (Figure 3A), suggesting that BRIT1
is required for surveillance of the DNA structure by these sen-
sors and early mediators. MDC1, 53BP1, and p-NBS1 associ-
ated at a low level with chromatin in the absence of exogenous
genome stress, suggesting that endogenous genomic stress
takes place during cell culture. In contrast to its effects on chro-
matin binding, BRIT1 knockdown did not change total levels of
MDC1, 53BP1, or NBS1 (Figure S3 and Lin et al., 2005). Thus,
the effects of BRIT1 knockdown on recruitment of these mole-
cules to chromatin probably resulted from changes in the148access or affinity of these molecules to the chromatin structure.
We used an anti-Orc2 antibody as the loading control because
the association of Orc2 to chromatin is not affected by DNA
damage (Zou et al., 2002).
BRIT1 depletion also markedly decreased UV-induced bind-
ing of two subunits of the RPA molecule (RPA70 and RPA34)
and of p-Rad17 to chromatin (Figure 3B). Following DNA dam-
age in the absence of BRIT1 depletion, chromatin bound
RPA34 was likely phosphorylated by ATR, as evidenced by
the formation of a heavy band upon probing with a p-RPA34 an-
tibody and by the band shift of total RPA34. These results impli-
cate BRIT1 in the recruitment of DNA damage sensors or early
mediators in the UV-triggered ATR pathway. We did not detect
significant changes in ATR binding to chromatin in BRIT1 knock-
down cells after UV irradiation (data not shown), which is consis-
tent with previous reports that UV induces foci formation, but not
chromatin binding, of ATR (Zou et al., 2002).
BRIT1 is required for the UV-induced phosphorylation
of RPA34 and Rad17
The DNA damage checkpoint is mediated by a cascade of
protein phosphorylation events. Sensors and mediators are
Figure 3. BRIT1 is required for the association of MDC1, 53BP1, p-NBS1, RPA,
and p-Rad17 with chromatin and for the UV-induced phosphorylation of
RPA and Rad17
A: U2OS cells were transfected twice with luciferase or with two different
BRIT1 siRNAs; at 48 hr after the second transfection, cells were treated or
not treated with 10 Gy of ionizing radiation. Two hours after irradiation, chro-
matin-enriched sediments were subjected to Western blot analysis and
probed with antibodies against BRIT1, MDC1, 53BP1, p-NBS1, NBS1, and
ORC2.
B: U2OS cells were transfected as described for A and treated with 50 J/m2
UV radiation; 2 hr later, chromatin-enriched fractions were subjected to
Western blotting and probed with antibodies against BRIT1, RPA70,
p-RPA34, RPA34, p-Rad17, Rad17, and ORC2.
C: U2OS cells were treated as described above except that cells were
exposed to 30 J/m2 of UV; 8 hr after irradiation, whole-cell lysates were col-
lected and subjected to Western blot analysis and probed with antibodies
against BRIT1, p-RPA34, RPA34, p-Rad17, and actin.CANCER CELL AUGUST 2006
A R T I C L EFigure 4. BRIT1 deficiency leads to chromosomal
aberrations
HMEC cells were mock transfected or trans-
fected with luciferase or one of three different
BRIT1 siRNAs twice; 72 hr later, cells were ana-
lyzed by metaphase spreads. The top panels
show examples of abnormal chromosomes,
and the bottom panel summarizes percentages
of cells containing chromosomal aberrations.recruited to DNA damage sites (chromatin) and then phosphor-
ylated by ATM or ATR to transmit signals to downstream medi-
ators, resulting in execution of DNA damage responses. Be-
cause BRIT1 depletion blocked the recruitment of those
sensors or mediators to foci and to chromatin, we next sought
to determine whether damage-induced phosphorylation of
these factors by ATM or ATR would consequently be abolished
by BRIT1 depletion. Indeed, BRIT1 depletion abolished the UV-
induced phosphorylation of RPA34, as evidenced by the ap-
pearance of a band upon treatment with an RPA34-Ser4/Ser8
p-antibody and by the band shift of total RPA34 (Figure 3C).
BRIT1 depletion also abolished the phosphorylation of Rad17
(Figure 3C). This effect could represent the failure of recruitment
of RPA34 and Rad17 to damaged DNA loci and/or the failure of
ATR to get access to phosphorylate RPA34 and Rad17.
BRIT1 deficiency increases the frequency
of chromosomal aberrations
Intact DNA damage pathways are crucial for maintaining geno-
mic integrity. Deficiencies of g-H2AX (Celeste et al., 2003),
NBS1 (Difilippantonio et al., 2005), and RPA (Wang et al.,
2005a) have all been shown to increase the accumulation of
chromosome aberrations. Because our findings clearly demon-
strated that BRIT1 has an important role in regulating the recruit-
ment of several essential checkpoint regulators to damaged
DNA, we assessed whether depletion of BRIT1 in cells would
lead to an increase in chromosome aberrations and genomic in-
stability. To test this hypothesis, we transfected normal human
mammary epithelial cells (HMECs) with control siRNA or with
three specific BRIT1 siRNAs. At 72 hr after the second transfec-
tion, cells were treated with colcemid and the chromosomes
were analyzed by metaphase spreads. BRIT1-depleted HMECs
showed a variety of chromosome aberrations, including chro-
mosomal breaks, dicentric chromosomes, and chromosomalCANCER CELL AUGUST 2006telomeric association (Figure 4). Chromosomal abnormalities
were detected in approximately 25%of BRIT1 knockdown cells,
with no chromosomal aberrations being detected in mock- or
control siRNA-treated cells (Figure 4). When pretreated with 3
Gy of ionizing radiation, the extent of chromosome aberration
was even more severe (80% of BRIT1 knockdown cells showed
aberrations). Similar sensitivity to chromosomal damage was
also observed when normal human fibroblast BJ cells, MCF7
cells, and HeLa cells were evaluated (data not shown). These
findings support the importance of BRIT1 in maintaining chro-
mosomal integrity with or without exogenous genotoxic stress.
BRIT1 is aberrant in human cancer
Failure of DNA damage checkpoint control leads to chromo-
somal aberrations (Gollin, 2005) and genomic instability (Eyfjord
and Bodvarsdottir, 2005), both of which contribute to neoplastic
transformation (Mills et al., 2003). We found that BRIT1, by its
regulation of key checkpoint regulators, was required for the
maintenance of chromosomal integrity in cells. Because BRIT1
is known to have a dual role in maintaining genomic stability
and in repressing hTERT, we anticipated that defects in BRIT1
may contribute to human cancer development.
Using high-density array comparative genomic hybridization
(CGH) (Snijders et al., 2001), we found substantial decreases
in BRIT1 DNA copy numbers in 35 of 87 cases (40%) of ad-
vanced epithelial ovarian cancer (Figure 5A). Interestingly, the
loss of gene copy number of BRIT1 significantly correlated
with overall genomic instability in these specimens. This result
is consistent with the role of BRIT1 in maintaining genomic in-
tegrity (Figure 5B). BRIT1 mRNA levels were also found to be
markedly decreased in 19 of 30 cases (63%) of ovarian cancer
specimens relative to BRIT1 mRNA levels in benign ovarian tis-
sue specimens (Figure 5C). Moreover, 72% of the 54 breast cell
lines tested also showed decreases in BRIT1 DNA copy number149
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A R T I C L E(Figure 5D). In comparing BRIT1 expression between nontrans-
formed breast epithelial cells (HMEC, MCF10A, and MCF10F)
and established breast cancer cell lines, we also found signifi-
cant decreases of BRIT1 RNA (Figure 5E) and protein
(Figure 5F, left panel) expression in the breast cancer lines.
We further determined if the decrease of BRIT1 in cancer cells
could contribute to defects in the activation of DNA damage re-
sponse. As shown in Figure 5F (right panel), formation of irradi-
ation-induced phospho-ATM containing foci were defective in
cancer cell lines (BT20 and MCF7: 20%–25% of cells contained
both BRIT1 and p-ATM foci) as compared to nontransformed
breast cell lines (HMEC and MCF10A: more than 90% of cells
contained both BRIT1 and p-ATM foci). The defect of p-ATM
foci formation was readily restored when BRIT1 was ectopically
expressed in MCF7 cells (Figure S4). These results, consistent
with the BRIT1 knockdown experiments described above, indi-
cate a crucial role of BRIT1 in early DNA damage responses.
We also examined the expression of BRIT1 in prostate cancer
specimens, which offer the opportunity to study the transition of
cells from normal to malignant in a single specimen. Immuno-
histochemical analysis revealed decreases of BRIT1 protein ex-
pression in benign prostate hypertrophy with further decreases
in cancer cells, as compared with surrounding normal prostate
tissue (Figure 5G).
Collectively, these findings suggest that changes in BRIT1
levels could contribute to tumor progression through increasing
genomic instability. Indeed, BRIT1 expression was inversely
correlated with the likelihood of breast cancer metastasis
(van’t Veer et al., 2002) (Figure 5H) and with the duration of re-
lapse-free survival (Wang et al., 2005b) (data not shown). In ad-
dition to the reduced expression of BRIT1, we also sought to de-
termine if genetic aberrations occurred within the BRIT1 coding
region in cancer specimens. After sequencing an entire 2.7 kb of
BRIT1 cDNA from ten breast cancer specimens, we identified
a 38 base pairBRIT1 deletion in exon 10 in one of the breast can-
cer specimens (BR7), which resulted in a premature stop codon
in exon 11 (Figure 6A). The same deletion was detected in the
plasmids of all cloned RT-PCR product analyzed from the
same patient sample, indicating that the deletion was not due
to the artifact from the RT-PCR process. Also, since no full-
length BRIT1 cDNA could be detected in this patient sample,
we suspect that there was an LOH in the other allele of BRIT1
gene. This deletion of BRIT1 led to a truncated protein withCANCER CELL AUGUST 2006a predicted size of 72 kd that lacked both the two C terminus
BRCT domains. Since BRCT domains are important for mediat-
ing DNA damage response (Yu et al., 2003), we suspected that
the BR7 mutant was defective for its function in response to
DNA damage. To address this question, we transfected U2OS
cells with empty FLAG vector (FLAG-V) or FLAG-BRIT1 or
FLAG-BR7 constructs with the endogenous BRIT1 knocked
down by BRIT1 siRNA. As expected, only FLAG-BRIT1, not
FLAG-V or FLAG-BR7, rescued the BRIT1-dependent MDC1
foci formation (Figure 6B). We also tested the function of
FLAG-BR7 in the BRIT1-deficient MCF7 cells. As shown in
Figure 6C, when ectopically expressed, FLAG-BRIT1 but not
FLAG-BR7 rescued the irradiation-induced formation of p-
RPA (left panel) or p-ATM foci (right panel).
Thus, we propose that BRIT1 functions as a tumor suppressor
gene that contributes to both cancer initiation and cancer pro-
gression in a variety of cancer lineages.
Discussion
The results presented here offer insight into a role of BRIT1
in mediating DNA damage signaling and in maintaining
chromosomal integrity. Collectively, these functions, in combi-
nation with the previously demonstrated functions of BRIT1 in
regulating BRCA1, Chk1, and hTERT, likely contribute to a tumor
suppressor role for BRIT1 (Figure 7).
We previously reported that BRIT1 regulated the expression
of two important checkpoint regulators, BRCA1 and Chk1,
and was required for maintenance of the intra-S and G2/M
checkpoints (Lin et al., 2005). In the same study, we also dem-
onstrated that BRIT1 was a chromatin binding protein that
formed IRIF after ionizing irradiation. Because BRIT1 foci colo-
calized with g-H2X foci, we hypothesized that, in addition to
the transcriptional regulation of BRCA1 and Chk1, BRIT1 might
participate directly in the transmission of DNA damage signal-
ing. Our findings herein revealed that BRIT1 indeed has a crucial
role in early DNA damage responses in both the ATM and ATR
pathways. ATM is the major kinase involved in immediate
responses to DSBs upon ionizing irradiation. In nonirradiated
cells, ATM is not phosphorylated and exists as an inactive dimer.
Following irradiation, DSBs trigger autophosphorylation of ATM
and formation of phosphorylated monomers (Bakkenist and Ka-
stan, 2003). The phosphorylated ATM monomers then relocateFigure 5. BRIT1 deficiencies in human cancer
A: Array-based CGH was used to test 87 specimens of human serous ovarian cancer with bacterial artificial chromosome probes. Log base two logarithmic
ratios of test to reference intensity were calculated for the probes across the region containing BRIT1. More than half of the samples arrayed showed a reduc-
tion in copy number, whereas approximately 30% showed a loss of at least one copy of the region across chromosome 8 encompassing BRIT1.
B: The losses of BRIT1gene copy in the ovarian cancer CGH database were compared with the gain or loss of at least one copy number change using different
probes to other chromosome regions. The specimens that exhibited more BRIT1 gene loss correlated with the overall copy changes of various genes.
C:Comparing BRIT1 RNA transcript levels in benign ovarian tissue specimens and ovarian tumor specimens demonstrated a statistically significant reduction in
BRIT1 RNA levels in the tumors as compared with the mean of RNA levels of the benign specimens.
D: CGH of 54 breast cancer cell lines showed that a striking majority showed large decreases in copy number, with loss of at least one copy, for the region on
chromosome 8 containing BRIT1.
E: Expression of BRIT1 RNA in human normal (untransformed) breast cell lines or breast cancer cell lines were analyzed by quantitative real-time RT-PCR.
F: Left: total cell lysates were obtained from the cultured cell lines, subjected to Western blot analysis, and probed with antibodies against BRIT1 or actin. Right:
the indicated cell lines were treated with 10 Gy of ionizing radiation. One hour after irradiation, cells were fixed and costained with antibodies to BRIT1 or
phospho-ATM antibody. Scale bar, 20 mm. Note: the phospho-ATM foci appeared in a very small fraction of BT20 or MCF7 cells that showed detectable
BRIT1 expression.
G: Prostate cancer specimens were analyzed by immunohistochemical staining and probed with BRIT1-specific antibody. The brownish color indicates BRIT1
expression in the regions of normal tissue, benign prostate hypertrophy (BPH), or prostate cancer from the same patient specimen. Scale bar, 50 mm.
H: BRIT1 RNA transcript levels were tested for correlation with time to metastasis of breast cancer in a database maintained by Stanford University. Normal to
high BRIT1 levels were associated with longer time to develop metastasis and an overall reduction in the incidence of metastasis.151
A R T I C L EFigure 6. The deleted BRIT1 gene identified from a breast cancer patient fails to activate foci formation for MDC1, p-RPA, and p-ATM
A: Exon 10 deletion of the BRIT1 gene (BR7) was identified in a breast patient sample by sequence analysis (coding exons shown in gray). The premature ter-
mination (indicated by red x, bottom schematic) results in a protein lacking two C terminus BRCT domains.
B: U2OS cells were transfected with FLAG-V, FLAG-BRIT1, or FLAG-BR7 constructs. Four hours after the transfection, cells were mock transfected or transfected
with control luciferase or BRIT1 siRNA#1. Forty-eight hours after the siRNA transfection, cells were treated with IR (10 Gy). One hour after irradiation, cells were
fixed and stained with the MDC1 antibody. Cells were then washed and subsequently stained with rhodamine-antibody. Nuclei were visualized by DAPI stain-
ing (left). Scale bars, 20 mm. The lysates from the cells analyzed above were subjected to Western blot analysis and probed with BRIT1 antibody (right) to con-
firm the expression of the exogenous FLAG-BRIT1 and FLAG-BR7 protein.152 CANCER CELL AUGUST 2006
A R T I C L Eto the DSBs and form the IRIF. Recent studies have implicated
MRN, possibly in a complex with MDC1 or 53BP1, in ionizing
irradiation-induced ATM activation (Goldberg et al., 2003; Lee
and Paull, 2005; Stewart et al., 2003). Because BRIT1 is required
for the recruitment of NBS1 (a component of theMRN complex),
MDC1, and 53BP1 to damaged DNA loci, it may function as
a key regulator in initiating the ATM-dependent response. In
fact, we found that knockdown of BRIT1 reduced IR-induced
Chk2, NBS1, and SMC1, but not ATM phosphorylation
(Figure S5; Lin et al., 2005), suggesting that BRIT1 was not re-
quired for autophosphorylation of ATM but the formation of
p-ATM foci and the ATM downstream signaling.
Our findings also implicate BRIT1 in the ATR pathway after UV
irradiation. Three complexes, RPA, ATR-ATRIP, and Rad17, are
among the earliest response elements in this pathway (Unsal-
Kacmaz et al., 2002; Zou and Elledge, 2003; Zou et al., 2003;
Sancar et al., 2004). UV irradiation results in increases in ssDNA,
which becomes coated by RPA (Zou and Elledge, 2003). The
RPA-coated ssDNA then recruits the ATR-ATRIP complex and
facilitates its recognition of substrates for phosphorylation and
signal transduction (Zou and Elledge, 2003). In fact, RPA is im-
portant not only for the recruitment of the ATR complex but
also for damage recognition by the Rad17 complex (Zou et al.,
2003). Our findings raise the possibility that BRIT1 regulates
the binding of the RPA to damaged DNA, which, in turn, recruits
the Rad17 complex to initiate the ATR signaling. While our man-
uscript was under review, a study on MCPH1/BRIT1 was pub-
lished in which the authors reported that MCPH1 had a function
downstream of Chk1 in the ATR-signaling pathway (Alderton
Figure 7. A model of BRIT1 functions in checkpoint signaling, chromosomal
integrity, and cancer suppression
In addition to regulating BRCA1 and Chk1 expression, BRIT1 is also required
for the function of DNA damage sensors or mediators in both the ATM
and ATR pathways; BRIT1 is also required for the maintenance of chromo-
somal integrity and, potentially, for tumor suppression.CANCER CELL AUGUST 2006et al., 2006). In fact, we also found a direct association between
BRIT1 and Chk1, suggesting that MCPH1/BRIT1 may regulate
the ATR signaling at multiple levels (data not shown). We should
note that the truncating mutations observed in MCPH syndrome
patients do not impact on Chk1 or BRCA1 expression or early
ATR-dependent damage-induced phosphorylation events (Al-
derton et al., 2006). As authors mentioned, the differential de-
fects observed may have been due to the different tissue types
or due to the incomplete loss of function of their mutants. There-
fore, the functional defects observed from the MCPH1 mutants
in microcephaly patients may be very different from the defects
in BRIT1 knockdown or in the cancer cells.
We also show here that BRIT1 depletion did not interfere with
the formation of radiation-induced g-H2AX foci, indicating that
BRIT1 functions in parallel with or downstream of g-H2AX in
the signal pathways. In fact, when we performed a kinetic study,
we observed enhanced g-H2AX levels and prolonged g-H2AX
responses in BRIT1 knockdown cells analyzed by Western
blot analysis (Figure S6A) and fluorescent staining
(Figure S6B). This observation may have been due to the im-
paired DNA repair in BRIT1 knockdown cells, a phenomenon
observed in Rpa1 mutant mice (Wang et al., 2005a). Since
both ATM and ATR signaling are defective when BRIT1 is
knocked down, the IR-induced H2AX phosphorylation in
BRIT1 knockdown cells is likely regulated by other kinases,
such as DNA-PK (Stiff et al., 2004). Indeed, DNA-PK inhibitor
dramatically reduced g-H2AX foci formation in the BRIT1 knock-
down cells (Figure S6C).
Disruption of the mechanisms that regulate DNA damage re-
sponses result in chromosomal aberrations and genomic insta-
bility. For example, haploinsufficiency for a variety of DNA dam-
age genes, including ATM, ATR, g-H2AX, and Chk1 (Barlow
et al., 1999; Bassing et al., 2003; Celeste et al., 2003; Fang
et al., 2004; Lam et al., 2004), or knockdown or knockout of
NBS1 (Difilippantonio et al., 2005; Zhang et al., 2005), RPA (Ba-
lajee and Geard, 2004; Wang et al., 2005a), Rad17 (Budzowska
et al., 2004), BRCA1 (Shen et al., 1998), and BRCA2 (Tutt and
Ashworth, 2002), is associated with genomic instability. Simi-
larly, cells lacking Rad17 were recently reported to exhibit acute
chromosomal aberrations including chromosomal breakage,
deletion, and endoduplication (Wang et al., 2003). siRNA knock-
down of ATR in cells has also been shown to drastically increase
chromosomal gaps and breaks (Casper et al., 2002). Consistent
with a crucial role of BRIT1 in controlling DNA damage re-
sponses, we found that BRIT1 depletion led to significant in-
creases in chromosomal aberrations in both nontransformed
cells and cancer cell lines. The types of aberrations identified im-
ply that BRIT1 knockdown probably leads to chromosomal in-
stability through breakage-fusion-bridge cycles and subse-
quent missegregation and breakage during mitosis.
Loss of DNA damage checkpoint function and acquisition of
the ability to proliferate indefinitely are two of the fundamental
changes required for the development of cancer. BRIT1 was
originally identified as an hTERT repressor that potentially pre-
vents hTERT reactivation and cellular immortalization. Recent
reports suggest that loss of the checkpoint responses isC: MCF7 cells were transfected with FLAG-V, FLAG-BRIT1, or FLAG-BR7 constructs. Forty-eight hours after transfection, cells were treated with either UV (50 J/m2)
or IR (10 Gy). One hour after irradiation, cells were fixed and stained with the p-RPA and p-ATM antibodies, respectively. Cells were then washed and
subsequently stained with rhodamine- or FITC-conjugated antibodies. Nuclei were visualized by DAPI staining. The lysates from the cells analyzed above
were subjected to Western blot analysis and probed with BRIT1 antibody (right) to confirm the expression of the exogenous FLAG-BRIT1 and FLAG-BR7 protein.153
A R T I C L Ea hallmark of cancer cells and is an early step in the development
of cancer (Bartkova et al., 2005; Gorgoulis et al., 2005; Kastan
and Bartek, 2004; Motoyama and Naka, 2004). Because
BRIT1 has a dual role in controlling these two critical activities,
we believe that BRIT1 deficiency may contribute to the develop-
ment of cancer in humans. BRIT1 is located on chromosome
8p23.1, a region implicated in the development of several malig-
nancies, including breast, ovarian, and prostate cancer (Chan
et al., 2002; DeMarzo et al., 2003; Lassus et al., 2001; Miller
et al., 2003; Pribill et al., 2001; Shao et al., 2000; Thor et al.,
2002; Veltman et al., 2003). Indeed, 8p23.1 is one of two most
common sites of allelic loss or chromosomal deletions in pros-
tate cancer (Bookstein, 2001; DeMarzo et al., 2003). Our find-
ings with regard toBRIT1 gene content and RNA and protein ex-
pression in different cancer specimens and the BRIT1 gene
aberration identified in a breast cancer patient are consistent
with a potential role of BRIT1 as a tumor suppressor gene. Fur-
ther, BRIT1 status seems to correlate with the occurrence of
metastasis and duration of the relapse-free interval in patients
with breast cancer, suggesting that BRIT1 may contribute to tu-
mor aggressiveness. Thus, BRIT1 defection seems to be a key
pathological alteration in cancer initiation and progression,
and as such, further understanding of its function may well con-
tribute to novel, effective therapeutic approaches for cancer.
Experimental procedures
Cells
U2OS cells and breast cancer cell lines were purchased from the American
Type Culture Collection (Manassas, VA). The U2OS cells were maintained
in McCoy’s 5A medium supplemented with 10% fetal bovine serum with glu-
tamine, penicillin, and streptomycin; the breast cancer cell lines were main-
tained in the recommended media. Normal human mammary epithelial cells
were purchased fromCambrexCorp. (East Rutherford, NJ) andmaintained in
Mammary Epithelial Basal Medium.
siRNA
The siRNA duplexes were 19 base pairs with a 2 base deoxythymidine over-
hang (Dharmacon Research). The sequences of BRIT1 siRNA#1, #2, and #3
oligonucleotides are AGGAAGUUGGAAGGAUCCAdTdT, CUCUCUGUGU
GAAGCACCUdTdT, and CUGGCGUAUACAAGAUGACdTdT, respectively.
The control Luciferase siRNA has the following sequence: UAAGGCUAU
GAAGAGAUACdTdT. Cells were transfected with siRNA duplexes using
Oligofectamine (Invitrogen) following the manufacturer’s instructions.
Antibodies
BRIT1 antibody was generated by using a GST-BRIT1 fusion protein synthe-
sized by Proteintech (Chicago, IL). Anti-ATR (N-19) and anti-Orc2 (C-18) an-
tibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA);
anti-p-Rad17 (Ser645), p-Chk2, and anti-p-NBS1 antibodies were pur-
chased from Cell Signaling Technology (Beverly, MA); anti-RPA70, anti-
NBS1, anti-p-ATM, and anti-g-H2AX antibodies were purchased from Up-
state Biotechnology (Lake Placid, NY); anti-ATM antibody was purchased
from Novus Biologicals (Littleton, CO); anti-RPA32 antibody was purchased
from Neomarkers (Fremont, CA); p-RPA32-Ser4/Ser8 and p-SMC1 anti-
bodies were purchased from Bethyl Laboratories (Montgomery, TX); and
MDC1 antibody was purchased from Sigma (St. Louis, MO).
Immunofluorescence staining
Cells cultured on coverslips were washed twice in phosphate-buffered saline
(PBS), incubated in cytoskeleton buffer (piperazine-N,N0-bis[2-ethanesul-
fonic acid] [pH 6.8], 100 mMNaCl, 300 mM sucrose, 3 mMMgCl2, 1 mM eth-
ylene glycol bis-2-aminoethyl ether-N,N0,N0 0,n0-tetraacetic acid [EGTA], and
0.5% Triton X-100) for 3 min on ice. The cells were then washed with ice-
cold PBS three times and incubated in stripping buffer (10 mM Tris-HCl
[pH 7.4], 10 mM NaCl, 3 mM MgCl2, 1% Tween 20, and 0.25% sodium154deoxycholate) for 3 min on ice. After another three washes with ice-cold
PBS, cells were fixed with 4% paraformaldehyde at 4C for 30 min, permea-
bilized in 1% Triton X-100 and 0.5% NP-40 for another 30 min, blocked with
1% bovine serum albumin, and incubated with primary antibody for 2 hr and
secondary antibody (fluorescein isothiocyanate, or rhodamine) for 1 hr. Cells
were then stained with 40,6-diamidino-2-phenylindole (DAPI) to visualize nu-
clear DNA. The coverslips were mounted onto glass slides with VectaShield
antifade (Vector Laboratories, Burlingame, CA) and visualized by using a Le-
ica DM LB fluorescence microscope. Images were captured with a Kodak
digital imaging system.
Chromatin isolation
A total of 4 3 106 cells were washed with PBS and resuspended in 200 ml of
solution A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M su-
crose, 10%glycerol, 1mMdithiothreitol, 10mMNaF, 1mMNa2Vo3, and pro-
tease inhibitors). Triton X-100 was added to a final concentration of 0.1%,
and the cells were incubated for 5min on ice. Cytoplasmic proteins were sep-
arated from nuclei by low-speed centrifugation (4 min at 1300 3 g at 4C).
The isolated nuclei were washed once with solution A and then lysed in
200 ml of solution B (3 mM ethylenediamine tetraacetic acid, 0.2 mM
EGTA, 1 mM dithiothreitol, and protease inhibitors). Insoluble chromatin
was collected by centrifugation (4 min at 1700 3 g at 4C), washed once in
solution B, and centrifuged again at high speed (10,000 3 g) for 1 min. The
final chromatin pellet was resuspended in 200 ml of Laemmli buffer and son-
icated for 15 s. Chromatin was digested by resuspending nuclei in solution A
containing 1 mMCaCl2 and 50 units of micrococcal nuclease (Sigma) and in-
cubating at 37C for 1 min, after which the nuclease reaction was stopped by
the addition of 1 mM EGTA.
Chromosome preparation
For chromosomal aberration studies, cells were transfected twice with con-
trol or BRIT1-specific siRNA. Seventy-two hours after the second siRNA
transfection, cytological preparations were made following standard proce-
dures. Briefly, cells were exposed to Colcemid (0.04 mg/ml) for 1 hr, subjected
to hypotonic treatment (0.075MKCl for 20–25min at room temperature), and
fixation in a mixture of methanol and acetic acid (3:1 by volume). Slides were
stained in Giemsa and examined blindly for structural and numerical abnor-
malities. These slides were decoded only after the entire scoring of aberra-
tions was completed. From each sample, a minimum of 35 metaphase
spreads were analyzed, and representative spreads were captured using
a Genetiscan imaging system.
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) was performed by using total
RNA (isolated with Trizol [Invitrogen]) and the one-step RT-PCR TaqMan
Fast Universal PCR Master Mix from Applied Biosystems (Foster City, CA).
A fluorogenic TaqMan probe for BRIT1 was designed based on a sequence
from Genbank, and a b-actin probe was used as the loading reference.
Immunohistochemical staining
Ten formalin-fixed, paraffin-embedded sections of prostate cancer tissues
obtained from the institutional prostate cancer bank were used for BRIT1 de-
tection as follows. After slides were deparaffinized with xylene and rehy-
drated through ethanol series, microwave antigen retrieval was carried out
by placing the slides in 0.1 M sodium citrate buffer (pH 6.0) in a microwave
oven at 98C for 8 min. Endogenous peroxidase activity was quenched
with 3%hydrogen peroxide inmethanol for 12min. Slides were washed three
times with PBS and incubated for 1 hr in protein blocking buffer (5% normal
horse serum plus 1% normal goat serum in PBS). Immunohistochemical
staining was done by using the Vectastain ABC avidin biotin-peroxidase en-
zyme complex kit (Vector Laboratories) and BRIT1 antibody (1:100 dilution).
Cells were visualized by adding 0.05% 3-30 diaminobenzidine and counter-
stained with Gill’s No. 3 hematoxylin. In parallel, cell pellets from BRIT1-
siRNA treated or untreated HMEC cells were processed at the same time
with the same staining procedure to serve as positive and negative staining
controls. The studies were performed according to protocols approved by
the University of Texas M.D. Anderson Cancer Center Institutional Review
Board, and all subjects provided written informed consent.CANCER CELL AUGUST 2006
A R T I C L EMutation analysis
For mutation analysis, full-length BRIT1 cDNAs were amplified from ten
breast cancer samples using SuperScript III One Step RT-PCR Platinum
Taq HiFi (Invitrogen). RT-PCR products were then cloned into Topo-XL
PCR vector (Invitrogen) for sequencing.
Array CGH
Array-based CGH was used to test 87 specimens of human serous ovarian
cancer with bacterial artificial chromosome probes as described by Pinkel
et al. (1998). Log base two logarithmic ratios of test to reference intensity
were calculated for the probes across the region containing BRIT1. The stud-
ies were performed according to protocols approved by the University of
Texas M.D. Anderson Cancer Center Institutional Review Board, and all sub-
jects provided written informed consent.
Supplemental data
The Supplemental Data include six supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/content/full/
10/2/145/DC1/.
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